CytRx (CYTR) trades 6% higher in premarket action.
Investors seem pleased with Tuesday's presentation at the LD MICRO Main Event Conference in L.A.
The company discussed aldoxorubicin, reviewed some data from on-going Phase 2 trials, and talked a bit about the upcoming Phase 3 study (Q1 2014 is planned start).
CYTR also presented a timeline, outlining "numerous upcoming catalysts."
Those interested can view the full presentation here.